Free Trial

Adaptimmune Therapeutics (ADAP) Competitors

Adaptimmune Therapeutics logo
$0.27 0.00 (-0.54%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$0.27 0.00 (-1.57%)
As of 08:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADAP vs. TNXP, ALLO, INZY, ALDX, CADL, ACB, SGMT, IMMP, CRDF, and FENC

Should you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Tonix Pharmaceuticals (TNXP), Allogene Therapeutics (ALLO), Inozyme Pharma (INZY), Aldeyra Therapeutics (ALDX), Candel Therapeutics (CADL), Aurora Cannabis (ACB), Sagimet Biosciences (SGMT), Prima BioMed (IMMP), Cardiff Oncology (CRDF), and Adherex Technologies (FENC). These companies are all part of the "pharmaceutical products" industry.

Adaptimmune Therapeutics vs. Its Competitors

Tonix Pharmaceuticals (NASDAQ:TNXP) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

In the previous week, Tonix Pharmaceuticals had 15 more articles in the media than Adaptimmune Therapeutics. MarketBeat recorded 17 mentions for Tonix Pharmaceuticals and 2 mentions for Adaptimmune Therapeutics. Adaptimmune Therapeutics' average media sentiment score of 0.75 beat Tonix Pharmaceuticals' score of -0.12 indicating that Adaptimmune Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tonix Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral
Adaptimmune Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Tonix Pharmaceuticals currently has a consensus price target of $585.00, indicating a potential upside of 1,281.02%. Adaptimmune Therapeutics has a consensus price target of $1.35, indicating a potential upside of 392.77%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Tonix Pharmaceuticals is more favorable than Adaptimmune Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tonix Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Adaptimmune Therapeutics
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29

Adaptimmune Therapeutics has a net margin of -38.91% compared to Tonix Pharmaceuticals' net margin of -1,313.87%. Tonix Pharmaceuticals' return on equity of -120.96% beat Adaptimmune Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tonix Pharmaceuticals-1,313.87% -120.96% -101.28%
Adaptimmune Therapeutics -38.91%-163.73%-23.65%

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. 0.0% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 12.7% of Adaptimmune Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Tonix Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500.

Adaptimmune Therapeutics has higher revenue and earnings than Tonix Pharmaceuticals. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tonix Pharmaceuticals$10.04M31.04-$130.04M-$1.96 thousand-0.02
Adaptimmune Therapeutics$178.03M0.41-$70.81M-$0.27-1.02

Summary

Adaptimmune Therapeutics beats Tonix Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Adaptimmune Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADAP vs. The Competition

MetricAdaptimmune TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$73.10M$2.96B$5.55B$9.02B
Dividend YieldN/A2.43%5.25%4.04%
P/E Ratio-1.0221.1127.1820.14
Price / Sales0.41180.13379.4880.15
Price / CashN/A42.7337.5058.41
Price / Book5.497.748.075.60
Net Income-$70.81M-$54.96M$3.16B$248.43M
7 Day Performance9.28%9.10%4.71%5.47%
1 Month Performance0.77%5.73%4.52%7.87%
1 Year Performance-77.88%2.79%30.82%18.75%

Adaptimmune Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADAP
Adaptimmune Therapeutics
2.429 of 5 stars
$0.27
-0.5%
$1.35
+392.8%
-76.9%$73.10M$178.03M-1.02490
TNXP
Tonix Pharmaceuticals
2.6601 of 5 stars
$35.44
-0.1%
$585.00
+1,550.7%
-31.7%$261.03M$10.09M-0.0250Trending News
ALLO
Allogene Therapeutics
2.8764 of 5 stars
$1.16
-2.5%
$8.44
+628.0%
-47.3%$260.29M$20K-0.94310News Coverage
Gap Up
INZY
Inozyme Pharma
3.4851 of 5 stars
$4.00
flat
$11.75
+193.8%
N/A$258.25MN/A-2.3750
ALDX
Aldeyra Therapeutics
2.689 of 5 stars
$4.35
+1.2%
$9.50
+118.4%
+41.2%$257.55MN/A-4.4810
CADL
Candel Therapeutics
2.6203 of 5 stars
$4.99
-2.2%
$22.00
+340.9%
+2.7%$255.53MN/A-3.7260Analyst Upgrade
ACB
Aurora Cannabis
0.353 of 5 stars
$4.43
-2.4%
N/A-17.6%$255.21M$246.72M40.271,130
SGMT
Sagimet Biosciences
2.0524 of 5 stars
$8.68
+5.2%
$26.60
+206.5%
+210.7%$253.07M$2M-4.938
IMMP
Prima BioMed
1.0505 of 5 stars
$1.68
-2.3%
$7.00
+316.7%
-18.0%$251.19M$5.14M0.002,021Positive News
CRDF
Cardiff Oncology
1.9149 of 5 stars
$3.65
-0.3%
$9.88
+170.5%
+88.2%$243.49M$680K-3.9720Analyst Forecast
FENC
Adherex Technologies
2.3274 of 5 stars
$8.47
-3.8%
$13.00
+53.5%
+50.7%$242.88M$47.54M-16.6110

Related Companies and Tools


This page (NASDAQ:ADAP) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners